| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | gefitinib (Iressa®) |
| Formulation | 250 mg film-coated tablet |
| Reference number | 379 |
| Indication | Treatment of adult patients with locally advanced or metastatic non small cell lung cancer with activating mutations of EGFR TK |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/05/2009 |
| NICE guidance | |